Marion Afonso, M.Sc

HEVA Rare Disease Business Partner
Sanofi, France

Poster(s):

• (223) Fitusiran Prophylaxis Reduces Episodic Treatment-Associated Costs of Managing Breakthrough Bleeds in Hemophilia
  Wednesday, October 29, 2025